炎症性肠病患者接种SARS-CoV-2 mRNA疫苗六个月后的抗体应答
该研究评估炎症性肠病患者完成标准SARS-CoV-2疫苗接种后6个月时的抗刺突抗体应答,并在部分患者中观察接种后6个月内的抗体动力学变化。
要点
- 炎症性肠病患者无论免疫抑制状态如何均推荐接种SARS-CoV-2疫苗。
- 免疫抑制药物对SARS-CoV-2疫苗应答的影响尚不明确。
- 已有研究显示接受不同疗法的炎症性肠病患者接种标准疫苗后可检测到抗体应答。
核心结论
- 该研究旨在评估炎症性肠病患者完成标准SARS-CoV-2疫苗接种后6个月时的抗刺突抗体应答。
研究设计与样本
- 研究纳入炎症性肠病患者,评估完成标准SARS-CoV-2疫苗接种后6个月的抗刺突抗体应答。
- 次要目的为在部分接种后患者中观察6个月内的抗体动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.
引用
- Frey S, Chowdhury R, Connolly CM, et al. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 34998996. doi:10.1016/j.cgh.2021.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。